Related references
Note: Only part of the references are listed.Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Matthew J. Korobey et al.
NEUROCRITICAL CARE (2021)
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
Castillo Renee et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding
Marwan Sheikh-Taha et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2020)
Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients
Teresa A. Allison et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2020)
Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage
Jennifer A. Frontera et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Is It Truly Alpha? Incidence of Thrombotic Events With Andexanet Alfa at a Single Academic Medical Center
Katie A. Parsels et al.
ANNALS OF EMERGENCY MEDICINE (2020)
Factor Xa Inhibitor-Related Intracranial Hemorrhage Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates
Nicholas G. Panos et al.
CIRCULATION (2020)
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
Megan E. Barra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage
Amarilis Giovino et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2020)
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa
Charlie J. Nederpelt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review
Olivia S. Costa et al.
BMJ OPEN (2020)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system
Emma P. DeLoughery et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
Melanie N. Smith et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Andexanet alfa-The first 150 days
Sarah E. Culbreth et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
Deepa R. J. Arachchillage et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
Marwan Sheikh-Taha
INTERNAL AND EMERGENCY MEDICINE (2019)
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Victoria M. Stevens et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
Maureane Hoffman et al.
INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE (2018)
FACTOR EIGHT INHIBITOR BYPASSING AGENT (FEIBA) FOR REVERSAL OF TARGET-SPECIFIC ORAL ANTICOAGULANTS IN LIFE-THREATENING INTRACRANIAL BLEEDING
Gordon Mao et al.
JOURNAL OF EMERGENCY MEDICINE (2017)
Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation
Lucas N. Marzec et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting A Scientific Statement From the American Heart Association
Amish N. Raval et al.
CIRCULATION (2017)
Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH
N. Khorsand et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors
Ramesh Grandhi et al.
WORLD NEUROSURGERY (2015)
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Jan Beyer-Westendorf et al.
BLOOD (2014)
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P. Piccini et al.
EUROPEAN HEART JOURNAL (2014)
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study
Ravi Sarode et al.
CIRCULATION (2013)
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Management of bleeding and coagulopathy following major trauma: an updated European guideline
Donat R. Spahn et al.
CRITICAL CARE (2013)
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Scott Kaatz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data
Theo Stijnen et al.
STATISTICS IN MEDICINE (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
B. I. Eriksson et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2009)
The binomial distribution of meta-analysis was preferred to model within-study variability
Taye H. Hamza et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument
K Slim et al.
ANZ JOURNAL OF SURGERY (2003)
Share Paper
